Trial reportHaematologica2016
Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients.
Abstract readClinical Trial, Phase IILetterMulticenter Study
In one paragraph
Trial report in Haematologica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Brentuximab vedotin addition to gemcitabine in relapsed or refractory peripheral T-cell lymphoma: a LYSA phase 2 study.Blood advances · 2025Trial
- Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma.Annals of hematology · 2019Trial
- Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis: An Analysis of Phase 2 Results.JAMA dermatology · 2017Trial
- Care Patterns, Outcomes, and Costs in Peripheral T-Cell Lymphoma Patients with First-Line Treatment in Routine Clinical Practice in Europe.Journal of blood medicine · 2026Article
- Molecular Insights into the Diagnosis of Anaplastic Large Cell Lymphoma: Beyond Morphology and Immunophenotype.International journal of molecular sciences · 2025Review
- Recent Advances in Understanding the Clinical Responses of Brentuximab Vedotin in Lymphoma and the Correlation with CD30 Expression.OncoTargets and therapy · 2025Review
- Evans Syndrome as a Possible Complication of Brentuximab Vedotin Therapy for Peripheral T Cell Lymphoma.Hematology reports · 2023Article
- Estimating long-term progression-free and overall survival in patients with peripheral T-cell lymphoma: A US population-based oncology simulation model based on 5-year results from the ECHELON-2 trial.Journal of managed care & specialty pharmacy · 2023Article
- Anti-CD30 antibody-drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives.Annals of hematology · 2023Review
- Case Report: A recurrent case of ALK-ALCL after autologous transplantation was successfully treated with BV + a modified CHEP chemotherapy containing mitoxantrone hydrochloride liposome with the addition of chidamide maintenance therapy.Frontiers in oncology · 2023Article
- Biology and Molecular Pathogenesis of Mature T-Cell Lymphomas.Cold Spring Harbor perspectives in medicine · 2021Review
- Allogeneic stem cell transplantation for peripheral T cell lymphomas: a retrospective study in 285 patients from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).Journal of hematology & oncology · 2020Article
- FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell Lymphoma.The oncologist · 2019Article
- Brentuximab vedotin: clinical updates and practical guidance.Blood research · 2017Review
- Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma.Haematologica · 2017Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Mathilde LamarqueInstitut IMAGINE, Unité INSERM U1163, Paris, France Département de Pathologie, Groupe Henri-Mondor Albert-Chenevier, Assistance Publique - Hôpitaux de Paris, Créteil, France Unité INSERM U955, Créteil, France.
Céline BossardService d'Anatomie et Cytologie Pathologiques, Centre Hospitalier Universitaire, Hôtel Dieu, Nantes, France.
Adrien ContejeanUnité Hémopathies Lymphoïdes, Groupe Henri Mondor Albert-Chenevier, Assistance Publique - Hôpitaux de Paris, Créteil, France Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, France.
Pauline BriceHôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, France.
Marie ParrensDépartement de Pathologie, Hôpital Pessac, Bordeaux, France.
Steven Le GouillService d'Hématologie Clinique, Unité d'Investigation Clinique, Centre Hospitalier Universitaire de Nantes, France Unité INSERM, UMR892 - CNRS, UMR 6299, Université de Nantes, France.
Josette BrièreDépartement de Pathologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, France.
Reda BouabdallahService d'onco-hématologie adulte, Institut Paoli-Calmettes, Marseille, France.
Danielle CanioniDépartement de Pathologie, Hôpital Necker, Assistance Publique, Hôpitaux de Paris, France.
Hervé TillyDépartement d'hématologie clinique, Centre Henri Becquerel, Rouen, France Unité INSERM U918, Centre Henri Becquerel, Rouen, France.
Brigitte BouchindhommeDépartement de pathologie, CHU de Lille, France.
Emmanuel BachyDépartement d'hématologie clinique, Hospices Civils de Lyon, Université Claude Bernard Lyon-1, Pierre Bénite, France Unité CNRS UMR5239, Lyon, France Faculté de médecine Lyon Sud Charles Mérieux, Hôpitaux de Paris, France.
Richard DelarueService d'Hématologie, Hôpital Necker, Assistance Publique, Hôpitaux de Paris, France.
Corinne HaiounUnité INSERM U955, Créteil, France Unité Hémopathies Lymphoïdes, Groupe Henri Mondor Albert-Chenevier, Assistance Publique - Hôpitaux de Paris, Créteil, France Université Paris Est, Créteil, France.
Philippe GaulardDépartement de Pathologie, Groupe Henri-Mondor Albert-Chenevier, Assistance Publique - Hôpitaux de Paris, Créteil, France Unité INSERM U955, Créteil, France Université Paris Est, Créteil, France philipe.gaulard@aphp.fr.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Gene Expression Regulation, NeoplasticAdultAgedAged, 80 and overAntineoplastic AgentsBrentuximab VedotinDrug Administration ScheduleDrug Dosage CalculationsFemaleFranceHumansImmunoconjugatesKi-1 AntigenLymphoma, T-Cell, PeripheralMaleMiddle AgedAntineoplastic AgentsBrentuximab VedotinImmunoconjugatesKi-1 Antigenbrentuximab vedotinprimary cutaneous T-cell lymphomarefractoryrelapsedsystemic anaplastic large-cell lymphoma
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.